Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS ANNOUNCES GRANT OF RESTRICTED STOCK UNITS

Defence Therapeutics Inc.'s board of directors has approved the grant of 200,000 incentive restricted stock units (RSUs) to Sebastien Plouffe, chief executive officer and director of the company, vesting immediately. Each RSU entitles the holder thereof to receive one common share of the company expiring on April 24, 2027, subject to the terms of the omnibus incentive plan of the company and applicable securities law hold periods.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting-edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most.

We seek Safe Harbor.